Quantified Evaluation of Whole Face 8-points Supra-periosteum High Molecular Weight Hyaluronic Acid Injection in Asian

Launched by CHANG CHANG CHENG · Mar 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to reduce wrinkles and improve facial fullness using a special type of injection called high molecular weight hyaluronic acid (HA). The trial aims to find out how effective this approach is for Asian adults experiencing signs of aging in their faces. Researchers will inject HA at eight specific points on the face and will monitor the participants before the treatment and again at 4, 12, and 24 weeks afterward to see how well it works.

To be eligible for the study, participants need to be between 20 and 60 years old, able to understand the study procedures, and willing to give written consent. However, certain individuals will not be able to participate, such as those with allergies to HA, pregnant or breastfeeding women, or those who have had recent facial treatments that could affect the results. If you join the study, you can expect to receive the injections and complete surveys about your experience and satisfaction with the results. This research could provide valuable information on how to achieve a more youthful appearance through safe and effective treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Men and women aged between 20 and 60.
• • 2. Subjects who are capable of understanding and comply with the study procedures, instructions, and visit schedule.
• • 3. Subjects who voluntarily decide to participate in the entire course of the trial and provide written consent in the Informed Consent Form.
• Exclusion Criteria:
• • 1. Subjects with a history of anaphylaxis, allergy hyaluronic acid products, or any component of devices.
• • 2. Subjects with autoimmune diseases/ received immune system and Subjects with diabetes mellitus.
• • 3. Subjects with a history of a hypertrophic scar.
• • 4. Pregnant or breastfeeding women.
• • 5. Subjects with epilepsy or underlying porphyria.
• • 6. When there is inactive disease (such as inflammation, infection or tumours) in or near the intended treatment site.
• • 7. Treatment procedure (e.g., bioresorbable fillers, laser/light therapies, botulinum toxin A injections, face lift, facial peels, excisional facial surgery, dermal photorejuvenation clinically significant oral or maxillofacial surgery, etc.) that may interfere with the treatment area or evaluation within 6 months prior to screening as determined by the Principal Investigator.
• • 8. The subject who received soft tissue augmentation as following at the investigational medical device injection site within 6 months prior to screening as determined by the Principal Investigator.
• • 9. The subject who received soft tissue augmentation near the injection site with any of the following at any time.
• • 10. Subjects with a scar or skin lesion at the investigational medical device injection site that may interfere with the judgment of the treatment effect.
• • 11. Subjects who participated in another clinical trial within 60 days prior to screening or plan to participate in another investigation during the course of this study.
• • 12. Subjects who plan to receive other wrinkle improvement treatment in the face during this trial.
• • 13. Subjects who are otherwise determined by the investigator as ineligible for this study.